Three key reasons to consider an investment in ProMIS Neurosciences
  • Massive market opportunity & unmet medical need

No therapies available today to stop progression of Alzheimer’s disease (AD). Total US AD healthcare costs > $500BB, expected to triple over next 10-15 years. ProMIS products are uniquely designed to block the toxic strains of Amyloid beta, to stop the fundamental, underlying driver causing death of brain neurons in AD.

  • Management team

Experienced, complementary management team with outstanding scientific and business advisory boards.

  • Significant risk mitigation/reduction of ProMIS proposed products

Big pharma spent $BB on failed, or partially successful clinical trials. Results of these trials clearly indicate the ideal target product profile, i.e., to succeed, products must target the toxic prion form of Amyloid beta, and not target the other forms of Amyloid beta.

ProMIS products are designed to target uniquely these toxic strains of Amyloid beta.

Company Financials and Filings may be viewed on the SEDAR site here.